Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
sIPV in adolescents and adults vs DTaP-IPV-Hib in infants
NCT07354269Phase 4Recruiting
- Sponsor
- Sinovac Biotech Ltd.
- Start
- Sep 2025
- Primary completion
- Apr 2026
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of Sabin strain inactivated poliovirus vaccine in poliomyelitis, sponsored by Sinovac Biotech Ltd. Primary endpoints: Seroconversion rate of neutralizing antibodies against three serotypes of polioviruses in adolescents at Day 30, Seroconversion rate of neutralizing antibodies against three serotypes of polioviruses in adults at Day 30 and 1 more. Started Sep 2025; status: recruiting.
02
Drugs
Sabin strain inactivated poliovirus vaccine
03
Conditions
poliomyelitis
Beyond the preview
Go deeper on NCT07354269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07354269.